Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: Results of a randomised phase III trial

Quality of Life Research

Volumn 18, Issue 7, 2009, Pages 853-861

  Curran, Desmond ^a   Pozzo, Carmelo ^b   Zaluski, Jerzy ^c   Dank, Magdalena ^d   Barone, Carlo ^b   Valvere, Vahur ^e   Yalcin, Suayib ^f   Peschel, Christian ^g   Wenczl, Miklós ^h   Goker, Erdem ⁱ   Bugat, Roland ^j  

^a Omega Research   (Ireland)

^b CATHOLIC UNIVERSITY   (Italy)

^c GREATER POLAND CANCER CENTRE   (Poland)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e Estonian Oncology Center   (Estonia)

^f HACETTEPE UNIVERSITY   (Turkey)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h Markusovszky Teaching Hospital   (Hungary)

ⁱ EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^j INSTITUT CLAUDIUS REGAUD   (France)

more..

Author keywords

Advanced gastric cancer; CPT 11; EORTC QLQ C30; EuroQoL; Irinotecan; Quality of life

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PHYSICAL FUNCTIONING SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMACH ADENOCARCINOMA; STOMATITIS; THERAPY EFFECT; THERMOMETER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; ESOPHAGOGASTRIC JUNCTION; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; QUALITY OF LIFE; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 69249222615     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-009-9493-z     Document Type: Article

References (35)

1. P Pisani DM Parkin F Bray J Ferlay 1999 Estimates of the worldwide mortality from 25 cancers in 1990 International Journal of Cancer 83 1 18 29 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M
2. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor et al. 2005 Cancer statistics, 2005 CA: A Cancer Journal for Clinicians 55 1 10 30 10.3322/canjclin.55.1.10
3. JL Dickson D Cunningham 2004 Systemic treatment of gastric cancer European Journal of Gastroenterology and Hepatology 16 3 255 263 10.1097/00042737-200403000-00003
4. R Bugat 2003 Irinotecan in the treatment of gastric cancer Annals of Oncology 14 Suppl 2 S37 S40
5. E Van Cutsem 2004 The treatment of advanced gastric cancer: New findings on the activity of the taxanes The Oncologist 9 Suppl 2 S9 S15
6. C Pozzo C Barone 2008 Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? The Oncologist 13 7 794 806 10.1634/theoncologist.2008-0082
7. A Wagner W Grothe J Haerting G Kleber A Grothey WE Fleig 2006 Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data Journal of Clinical Oncology 24 18 2903 2909 10.1200/JCO.2005.05.0245
8. O Bouche JL Raoul F Bonnetain M Giovannini PL Etienne G Lledo et al. 2004 Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803 Journal of Clinical Oncology 22 21 4319 4328 10.1200/JCO.2004.01.140
9. I Chau AR Norman D Cunningham JS Waters J Oates PJ Ross 2004 Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data Journal of Clinical Oncology 22 12 2395 2403 10.1200/JCO.2004.08.154
10. (1996). Outcomes of cancer treatment for technology assessment and cancer treatment guidelines: American Society of Clinical Oncology. Journal of Clinical Oncology, 14(2), 671-679.
11. A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe et al. 1997 Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer Journal of Clinical Oncology 15 1 261 267
12. P Ross M Nicolson D Cunningham J Valle M Seymour P Harper et al. 2002 Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer Journal of Clinical Oncology 20 8 1996 2004 10.1200/JCO.2002.08.105
13. DH Ilson 2002 Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: A step ahead? Journal of Clinical Oncology 20 8 1962 1964
14. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni et al. 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group Journal of Clinical Oncology 24 31 4991 4997 10.1200/JCO.2006.06.8429
15. JA Ajani VM Moiseyenko S Tjulandin A Majlis M Constenla X Boni et al. 2007 Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group Journal of Clinical Oncology 25 22 3210 3216 10.1200/JCO.2006.08.3956
16. C Blanke D Haller AB Benson ML Rothenberg J Berlin M Mori et al. 2001 A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma Annals of Oncology 12 1575 1580 10.1023/A:1013129315036
17. N Boku A Ohtsu Y Shimada K Shirao S Seki H Saito et al. 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer Journal of Clinical Oncology 17 1 319 323
18. JA Ajani 2000 Standard chemotherapy for gastric carcinoma: Is it a myth? Journal of Clinical Oncology 18 23 4001 4003
19. M Moehler A Eimermacher J Siebler T Höhler A Wein M Menges et al. 2005 Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer British Journal of Cancer 92 12 2122 2128 10.1038/sj.bjc.6602649
20. C Pozzo C Barone J Szanto E Padi C Peschel J Bükki et al. 2004 Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study Annals of Oncology 15 12 1773 1781 10.1093/annonc/mdh473
21. M Dank J Zaluski C Barone V Valvere S Yalcin C Peschel et al. 2008 Randomized phase III study of irinotecan combined with 5-fluoruracil and folinic acid and cisplatin combined with 5-fluoruracil in palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Annals of Oncology 19 8 1450 1457 10.1093/annonc/mdn166
22. T Morikawa M Yoshida 1995 A useful testing strategy in phase III trials: Combined test of superiority and test of equivalence Journal of Biopharmaceutical Statistics 5 3 297 306 10.1080/10543409508835115
23. S Holm 1979 A simple sequentially rejective multiple test procedure Scandinavian Journal of Statistics 6 65 70
24. J Freedman SJ White 1976 On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial Biometrics 32 691 694 10.2307/2529759
25. Fayers, P. M., Aaronson, N. K., Bjordal, K., Curran, D., & Groenvold, M. (1999). EORTC QLQ-C30 scoring manual (2nd ed.). Brussels: EORTC.
26. P Kind 1996
27. D Machin S Weeden 1998 Suggestions for the presentation of quality of life data from clinical trials Statistics in Medicine 17 5-7 711 724 10.1002/(SICI)1097-0258(19980315/15)17:5/7<711::AID-SIM816>3.0.CO;2-H
28. D Curran G Molenberghs PM Fayers D Machin 1998 Incomplete quality of life data in randomized trials: Missing forms Statistics in Medicine 17 5-7 697 709 10.1002/(SICI)1097-0258(19980315/15)17:5/7<697::AID-SIM815>3.0.CO;2-Y
29. Diggle, P. J., Liang, K. Y., & Zeger, S. L. (1994). Analysis of longitudinal data. Oxford: Clarendon Press.
30. Verbeke, G., & Molenberghs, G. (1997). Linear mixed models in practice. New York: Springer-Verlag.
31. D Curran G Molenberghs NK Aaronson SD Fossa RJ Sylvester 2002 Analysing longitudinal continuous quality of life data with dropout Statistical Methods in Medical Research 11 1 5 23 10.1191/0962280202sm270ra
32. F Efficace A Bottomley 2002 Do quality-of-life randomized clinical trials support clinicians in their decision-making? Journal of Clinical Oncology 20 19 4126 10.1200/JCO.2002.99.117
33. Moehler, M., Trarbach, T., Seufferlein, T., Kubicka, S., Lordick, F., Geissler, M., et al. (2007). Cetuximab with irinotecan/Na-FA/5-FU as first-line treatment in advanced gastric cancer. European Journal of Cancer, 5(4), Abstract 3518.
34. C Pinto F Di Fabio S Siena S Cascinu FL Rojas Llimpe et al. 2007 Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocancinoma (FOLCETUX study) Annals of Oncology 18 3 510 517 10.1093/annonc/mdl459
35. MA Shah RK Ramanathan DH Ilson A Levnor D D'Adamo E O'Reilly et al. 2006 Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma Journal of Clinical Oncology 24 33 5201 5206